3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3,3-diMethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]Methyl]-benzaMide

3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3,3-diMethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]Methyl]-benzaMide Suppliers list
Company Name: J & K SCIENTIFIC LTD.  
Tel: 18210857532 18210857532
Email: jkinfo@jkchemical.com
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Company Name: Shanghai TaoSu Biochemical Technology Co., Ltd.  
Tel: 021-33632979
Email: info@tsbiochem.com
Company Name: EMMX Biotechnology LLC  
Tel: 888-539-0666
Email: info@emmx.com
Company Name: Shanghai Chaolan Chemical Technology Center  
Tel: QQ:65489617 13301690235
Email: Sales@ATKchemical.com

3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3,3-diMethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]Methyl]-benzaMide manufacturers

  • ML218
  • ML218 pictures
  • $517.00
  • 2026-07-14
  • CAS:1346233-68-8
  • Purity: 99.20%
  • Supply Ability: 10g
3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3,3-diMethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]Methyl]-benzaMide Basic information
Product Name:3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3,3-diMethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]Methyl]-benzaMide
Synonyms:3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3,3-diMethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]Methyl]-benzaMide;CID 45115620;ML218;VU0413807;VU0424199-1;ML 218 hydrochloride;3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3,3-dimethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-benzamide hydrochloride;Benzamide, 3,5-dichloro-N-[[(1α,5α,6α)-3-(3,3-dimethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-
CAS:1346233-68-8
MF:C19H26Cl2N2O
MW:369.33
EINECS:
Product Categories:Aromatics, Inhibitors, Pharmaceuticals, Intermediates & Fine Chemicals
Mol File:1346233-68-8.mol
3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3,3-diMethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]Methyl]-benzaMide Structure
3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3,3-diMethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]Methyl]-benzaMide Chemical Properties
Boiling point 455.5±35.0 °C(Predicted)
density 1.184±0.06 g/cm3(Predicted)
storage temp. 2-8°C
solubility DMSO: soluble10mg/mL (clear solution)
form powder
pka13.65±0.46(Predicted)
color white to beige
InChI1S/C19H26Cl2N2O/c1-19(2,3)4-5-23-10-16-15(17(16)11-23)9-22-18(24)12-6-13(20)8-14(21)7-12/h6-8,15-17H,4-5,9-11H2,1-3H3,(H,22,24)/t15-,16-,17+
InChIKeyGSJIGYLGKSBYBC-OSYLJGHBSA-N
SMILESCC(C)(C)CCN1C[C@H]2C(CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1
Safety Information
WGK Germany 3
Storage Class11 - Combustible Solids
MSDS Information
3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3,3-diMethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]Methyl]-benzaMide Usage And Synthesis
UsesThis compound, referred to as ML218, is a centrally active calcium channel inhibitor with potential applications to treatment of pain, epilepsy and neurological disorders through further study.
DefinitionChEBI: 3,5-dichloro-N-[[(1S,5R)-3-(3,3-dimethylbutyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]benzamide is an organohalogen compound and a carbonyl compound.
Biological ActivityML218 (CID 45115620) is a potent and selective T-Type (Cav3.1, Cav3.2, Cav3.3) calcium channel inhibitor (Cav3.2, IC50 = 150 nM in Ca2+ flux; Cav3.2 IC50 = 310 nM and Cav3.3 IC50 = 270 nM with good Drug metabolism/Pharmacokinetics. In a panel of 68 GPCRs, ion channels and transporters, ML218 was found to bind significantly only two other targets (sodium channel site 2 and sigma 1) and had no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. It showed robust inhibition of calcium current in STN neurons and was orally active in a rodent model of Parkinson′s Disease.
in vivo

ML218 (0.03-30 mg/kg; oral administration; once; male Sprague-Dawley rats) treatment reverses cataleptic behavior in rats induced by a 0.75 mg/kg dose of haloperidol[1].
Free brain and plasma concentrations of ML218 increases in a dose proportional manner across the dose range (3 mg/kg: [plasma] = 98 nM, [brain] = 1.66 μM; 10 mg/kg: [plasma] = 282 nM, [brain] = 5.03 μM; 30 mg/kg: 1.2 μM, [brain] = 17.7 μM)[1].
Noncompartmental pharmacokinetic analysis indicates ML218 (1 mg/kg, IV) has a mean residence time (MRT) of nearly 7 h, a value which is consistent with its terminal half-life (t1/2 = 7 h)[1].

Animal Model:Male Sprague-Dawley rats (275-299 g) induced by haloperidol[1]
Dosage:0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg
Administration:Oral administration; once
Result:Reversed cataleptic behavior in rats induced by a 0.75 mg/kg dose of haloperidol.
IC 50T-type calcium channel
3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3,3-diMethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]Methyl]-benzaMide Preparation Products And Raw materials
Tag:3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3,3-diMethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]Methyl]-benzaMide(1346233-68-8) Related Product Information
ML418 4-Methyl-2-(1-piperidinyl)-quinoline ML 133 Hydrochloride ML-252 (hydrochloride) ML365 ISX 9